Branded held a 65.61% share of the gastrointestinal therapeutics market in 2025, reflecting its continued lead across treatment areas where physician familiarity, established efficacy profiles, and strong brand recognition still shape prescribing behavior. This position is sustained by the role of branded therapies in managing complex gastrointestinal conditions that often require trusted treatment outcomes, especially where patients and clinicians are less willing to switch quickly based on price alone. Market leadership also benefits from the commercial strength and clinical positioning that branded products typically maintain within specialist-led care pathways.

Generics are the fastest-growing segment in the gastrointestinal therapeutics market as cost sensitivity becomes a stronger purchasing factor across healthcare systems and patient populations. Their momentum is aided by broader acceptance of lower-cost therapeutic alternatives in high-volume gastrointestinal indications, particularly where long-term treatment use makes affordability more important than brand preference. Compared with branded options, generics are gaining ground because they align more directly with efforts to expand treatment access while managing prescription spending.

Route of Administration Segment Analysis: Oral (Largest Segment) vs Injectable (Fastest-Growing Segment)

In 2025, oral accounted for a 56.97% share of the gastrointestinal therapeutics market, making it the leading route of administration due to its convenience, ease of long-term use, and fit with routine treatment patterns in gastrointestinal care. Oral therapies remain dominant because many gastrointestinal disorders require sustained symptom management rather than procedure-based intervention, and this supports strong patient adherence in everyday settings. The segment’s leadership is also reinforced by prescribing habits that favor practical, non-invasive administration for both chronic and common gastrointestinal conditions.

Injectable is emerging as the fastest-growing route in the gastrointestinal therapeutics market because it is increasingly associated with treatment settings that require targeted, rapid, or closely managed therapeutic delivery. Growth is being driven by expanding use in patients whose condition severity, response profile, or care setting makes oral administration less suitable. Relative to oral alternatives, injectable therapies are gaining momentum where clinical control and administration precision matter more than convenience, supporting faster uptake in more specialized gastrointestinal treatment scenarios.